Eisai's Alzheimer's hopeful lecanemab may have contributed to patient death: report

A month after Eisai reported positive, topline phase 3 data of its Alzheimer’s treatment lecanemab, STAT News is out with a new bombshell report that gut-checks the drug’s hype.